Myositis
Focused antibody testing to diagnose, classify disease, and tailor treatment
The use of myositis specific antibody (MSA) testing is an important tool in the diagnosis and classification of idiopathic inflammatory myopathies (IIM) subtypes. Advanced laboratory testing that evaluates MSAs, used as a supplement to traditional diagnostic approaches, can pinpoint diagnosis and classify IIM subtypes. Results from MSA testing can inform additional testing and help predict treatment response. 1, 2
Our focused MSA panel provides rapid answers that expedite diagnosis and treatment. This novel test:
- Offers an industry-leading time to results of 3–7 days.
- Features unique HMGCR and SRPIS antibodies, which are associated with necrotizing autoimmune myopathy (NAM).
- Automatically reflexes to confirmation and antibody level measurement if SRPIS antibodies are recognized.
Myositis antibody test menu
Myositis antibody evaluation
Diagnosing IIM subtypes can be challenging due to symptom overlap and seemingly unrelated extra-muscular presentations. However, accurate diagnosis is imperative since treatment can assist with symptom management and, in many cases, lead to remission.
Our focused MSA antibody panel includes 12 clinically relevant MSAs carefully selected for their direct association to IIM subtypes. Test results equip healthcare professionals with individualized information to reduce diagnostic uncertainty and set their patients on the best treatment path.
Key testing
- MSAES | Myositis Specific Antibody Evaluation, Serum
- Enables early detection of IIM, particularly atypical or severe cases.
- Uses indirect immunofluorescence assay (IFA) to evaluate MSA.
- Included antibodies were carefully selected for their direct associations to IIM subtypes.
- MSAs enable precise phenotyping and stratification of IIM subtypes, providing insights into associated extra-muscular disease activity, disease prognosis, and therapeutic responses.
- If IFA patterns indicate signal recognition particle (SRP) antibodies, then SRP IFA titer and SRP54 immunoblot will automatically reflex at an additional charge.
Included antibodies
| Test ID | Reporting name |
|---|---|
| EJS | EJ Ab, S |
| HMGCR | HMG-CoA Reductase Ab, S |
| JO1 | Jo 1 Ab, IgG, S |
| MDA5S | MDA5 Ab, S |
| MI2S | Mi2 Ab, S |
| NXP2S | NXP2 Ab, S |
| OJS | OJ Ab, S |
| PL12S | PL12 Ab, S |
| PL7S | PL7 Ab, S |
| SAE1S | SAE1 Ab, S |
| SRPIS | SRP IFA Screen, S |
| TIFGS | TIF1G Ab, S |
References
- Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007;66(10):1345-1349
- Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support the diagnosis of myositis. J Intern Med. 2016;280(1):8-23